Evaluation of the Sylimarin Effect on IL-10 and IL-17 Production in Blood Samples of Chronic HCV Infected Patients
Archives of Medical Laboratory Sciences,
Vol. 5 No. 2 (2019),
20 March 2019
,
Page 10-14
https://doi.org/10.22037/amls.v5i2.29771
Abstract
Background: The use of herbal remedies, either in combination with conventional drugs or as an alternative, is accepted worldwide. Silymarin derived from Milk thistle has evidence-based therapeutic potency for wide spectrum of liver diseases. The current work aimed to study the immune-modulating activity of Silymarin in HCV-infected patients by measuring the effect of pure Silymarin solution on the production of IL-17 and IL-10. Materials and Methods: Nine HCV-1a infected patients and three healthy controls were entered in this study. The mean age of patients and healthy controls were 45.53 (± 10.21) and 39.9 (±10.88), respectively. The PBMCs were isolated, cultured in 96-well plate and incubated with Silymarin solution (5µg/ml) for 24 hours. The cells and cell culture supernatant of three groups including patients treated with Silymarin, non-treated patients, and healthy controls were then subjected to Real Time PCR and ELISA to measure the levels of inflammatory and non-inflammatory cytokines including IL-17 and IL-10, respectively. Statistical analysis was conducted using SPSS software version 20.0. Results: According to Real Time PCR and ELISA results, the level of IL-17 was significantly reduced in patients treated with Silymarin while the expression of IL-10 was remarkably increased in these patients. Conclusion: The results of this study approved the immunomodulatory properties of Silymarin in HCV-infected patients. Hepatoprotective, antiviral, as well as immunomodulatory properties of the Silymarin make it a potential therapeutic option in patients with chronic hepatitis C.
- Sylimarin
- Hepatitis C Virus (HCV)
- Interleukin 10 (IL-10)
- Interleukin 17 (IL-17)
- Real Time PCR
- ELISA
How to Cite
References
Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature medicine. 2013;19(7):837.
Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. American family physician. 2010;81(11):1351-7.
Lam N-CV, Gotsch PB, Langan RC. Caring for pregnant women and newborns with hepatitis B or C. American family physician. 2010;82(10):1225-9.
Sesmero E, Thorpe IF. Using the hepatitis C virus RNA-dependent RNA polymerase as a model to understand viral polymerase structure, function and dynamics. Viruses. 2015;7(7):3974-94.
Alter MJ. Epidemiology of hepatitis C virus infection. World journal of gastroenterology: WJG. 2007;13(17):2436.
Bruno CM, Valenti M, Bertino G, Ardiri A, Amoroso A, Consolo M, et al. Relationship between circulating interleukin-10 and histological features in patients with chronic C hepatitis. Annals of Saudi medicine. 2011;31(4):360-4.
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. New England Journal of Medicine. 2009;361(9):888-98.
Scott Luper N. A review of plants used in the treatment of liver disease: part 1. Alternative medicine review. 1998;3(6):410-21.
Muriel P, Garciapiña T, Perez‐Alvarez V, Mourelle M. Silymarin protects against paracetamol‐induced lipid peroxidation and liver damage. Journal of Applied Toxicology. 1992;12(6):439-42.
Kazazis CE, Evangelopoulos AA, Kollas A, Vallianou NG. The therapeutic potential of milk thistle in diabetes. The review of diabetic studies: RDS. 2014;11(2):167.
Rao PR, Viswanath RK. Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. Experimental & Clinical Cardiology. 2007;12(4):179.
Rafieian-Kopaie M, Nasri H. Silymarin and diabetic nephropathy. Journal of renal injury prevention. 2012;1(1):3.
Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DYW. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized silymarin. Gastroenterology. 2007;132(5):1925-36.
Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis. The Journal of Immunology. 1999;163(12):6800-9.
Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, et al. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-κB activity and IL-2 production. Pharmacological research. 2010;61(5):405-9.
Bannwart CF, Nakaira-Takahagi E, Golim MA, de Medeiros LTL, Romão M, Weel IC, et al. Downregulation of nuclear factor-kappa B (NF-κB) pathway by silibinin in human monocytes challenged with Paracoccidioides brasiliensis. Life sciences. 2010;86(23-24):880-6.
Dupuis ML, Conti F, Maselli A, Pagano MT, Ruggieri A, Anticoli S, et al. The natural agonist of estrogen receptor β silibinin plays an immunosuppressive role representing a potential therapeutic tool in rheumatoid arthritis. Frontiers in immunology. 2018;9:1903.
Esmaeil N, Anaraki S, Gharagozloo M, Moayedi B. Silymarin impacts on immune system as an immunomodulator: One key for many locks. International Immunopharmacology. 2017;50:194-20.
- Abstract Viewed: 336 times
- pdf Downloaded: 162 times